Cited by 101Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) ResearchPharmaceutical Economics and Policy

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis

Dempsey, Timothy M., Payne, Stephanie, Sangaralingham, Lindsey, Yao, Xiaoxi, Shah, Nilay D., Limper, Andrew H.·2021·Annals of the American Thoracic Society

DOI 10.1513/annalsats.202007-901oc

Open this paper in CoChat — free account

Abstract

Abstract Rationale In October 2014, the antifibrotic medications pirfenidone and nintedanib became the first medications approved by the U.S. Food and Drug Administration for use in patients with idiopathic pulmonary fibrosis (IPF). Since approval, there has been no nonregistry analysis of the real-world adoption of these medications in everyday clinical practice. Objectives To evaluate the adoption, persistence, and out-of-pocket (OOP) costs of pirfenidone and nintedanib since their approval in the United States in 2014. Methods A retrospective cohort analysis was performed by identifying privately insured and Medicare Advantage beneficiaries with IPF. We then split the patients into three cohorts: those who were untreated and those who filled a prescription for either pirfenidone or nintedanib between October 1, 2014, and July 31, 2019. The primary outcome was adoption of the medications. Secondary outcomes included medication persistence and prescription drug costs. Results A total of 10,996 patients with IPF were identified in the data set. A minority of patients (26.4%) with IPF identified in the cohort had started either medication since approval in 2014, with the adoption of both medications being comparable at around 13.2%. Those receiving the medications were younger (72 vs. 73.9 yr; P < 0.0001) and healthier (3.9 vs. 4.9 comorbidities; P < 0.0001) than those not receiving treatment. Men were significantly more likely to receive treatment than woman (30.0% vs. 21.9%; P < 0.0001). Among treated patients, 42.8% discontinued the medications during the study period. Patients’ OOP expenses per month were high for both drugs (mean, $397.51 for nintedanib; mean, $394.49 for pirfenidone). Conclusions The adoption of both the antifibrotic medications in the United States in everyday practice has been low since approval and may be associated with the high OOP cost.

Integrity signals

Registry

Crossref · 10.1513/annalsats.202007-901oc

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Medication compliance and persistence: terminology and definitions
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00213.x · Cited by 2,220
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,654
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310
Idiopathic Interstitial Pneumonia
Flaherty, K. R., King, T. E., Raghu, G., Lynch, J. P., Colby, T. V., Travis, W. D., Gross, B. H., Kazerooni, E. A., Toews, G. B., Long, Q., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200402-147oc · Cited by 672
Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial
Raghu, G., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Nathan, S. D., Wells, A. U., Collard, H. R., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-9-201305070-00003 · Cited by 553
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531

Show all 33 references

Research works printed but not linked: 4

Flaherty, 2018, Baseline characteristics of 1461 participants in the pulmonary fibrosis foundation patient registry [abstract], Eur Respir J, 52, PA2199
Wong, 2018, Direct oral anticoagulant prescription trends, switching patterns, and adherence in Texas Medicaid, Am J Manag Care, 24, SP309
Achaiah, 2017, Tolerability and efficacy of pirfenidone and nintedanib for patients with IPF in real world clinical practice [abstract], Eur Respir J, 50, PA4879
Eaddy, 2012, How patient cost-sharing trends affect adherence and outcomes: a literature review, P&T, 37, 45

Sorted by citations

Idiopathic pulmonary fibrosis: Current and future treatment
Glass, D. S., Grossfeld, D. J., Renna, H. A., Agarwala, P., Spiegler, P. A., DeLeon, J. R., & Reiss, A. B. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13466 · Cited by 322
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
Chianese, M. I., Screm, G., Salton, F., Confalonieri, P., Trotta, L., Barbieri, M., Ruggero, L., Mari, M., Reccardini, N., Geri, P., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17060709 · Cited by 113
Sex and gender in interstitial lung diseases
Kawano-Dourado, L. B., Glassberg, M. K., Assayag, D., Borie, R., & Johannson, K. A. (2021) · European Respiratory Review · doi:10.1183/16000617.0105-2021 · Cited by 67
Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment
Herberts, M. B., Teague, T., Thao, V., Sangaralingham, L. R., Henk, H. J., Hovde, K. T., Dempsey, T. M., & LIMPER, A. H. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02565-7 · Cited by 47
Self-citation
The novel molecular mechanism of pulmonary fibrosis: insight into lipid metabolism from reanalysis of single-cell RNA-seq databases
Shi, X., Chen, Y., Shi, M., Gao, F., Huang, L., Wang, W. J., Wei, D., Shi, C., Yu, Y., Xia, X., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02062-8 · Cited by 44
Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis
Teague, T., Payne, S. R., Kelly, B. T., Dempsey, T. M., McCoy, R. G., Sangaralingham, L. R., & LIMPER, A. H. (2022) · Respiratory Research · doi:10.1186/s12931-022-02001-0 · Cited by 50
Self-citation
PCSK6 and Survival in Idiopathic Pulmonary Fibrosis
Oldham, J. M., Allen, R. J., Lorenzo-Salazar, J. M., Molyneaux, P. L., Ma, S., Joseph, C., Kim, J. S., Guillén‐Guío, B., Hernández-Beeftink, T., Kropski, J. A., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202205-0845oc · Cited by 42
Progressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium
Bridges, J. P., Vladar, E. K., Kurche, J. S., Krivoi, A., Stancil, I. T., Dobrinskikh, E., Hu, Y., Sasse, S. K., Lee, J. S., Blumhagen, R. Z., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci183836 · Cited by 40
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
Nathan, S. D., Smith, P., Deng, C., Salvo, M. D., Wuyts, W. A., Gallegos, J. P., Song, J. M., Kramer, M. R., King, C., Mackintosh, J. A., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2512911 · Cited by 33
A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review
Man, R. K., Gogikar, A., Nanda, A., Janga, L. S. N., Sambe, H. G., Yasir, M., & Ramphall, S. (2024) · Cureus · doi:10.7759/cureus.54268 · Cited by 30
Relative environmental and social disadvantage in patients with idiopathic pulmonary fibrosis
Avitzur, N., Noth, E. M., Lamidi, M., Nathan, S. D., Collard, H. R., DeDent, A. M., Thakur, N., & Johannson, K. A. (2021) · Thorax · doi:10.1136/thoraxjnl-2021-217652 · Cited by 27
Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
Dempsey, T. M., Thao, V., Moriarty, J. P., Borah, B. J., & LIMPER, A. H. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01811-0 · Cited by 25
Self-citation
Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols
Patel, H., Shah, J. R., Patel, D., Avanthika, C., Jhaveri, S., & Gor, K. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101484 · Cited by 21
Regulator of Cell Cycle Protein (RGCC/RGC-32) Protects Against Pulmonary Fibrosis
Luzina, I. G., Rus, V., Lockatell, V., Courneya, J.-P., Hampton, B., Fishelevich, R., Misharin, A. V., Todd, N. W., Badea, T. C., Rus, H., et al. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0022oc · Cited by 19
Interstitial lung disease progression after genomic usual interstitial pneumonia testing
Chaudhary, S., Weigt, S. S., Neto, M. L. R., Benn, B. S., Pugashetti, J. V., Keith, R. C., Chand, A., Oh, S., Kheir, F. M., Ramalingam, V. S., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01245-2022 · Cited by 20
A randomized phase 1 evaluation of deupirfenidone, a novel deuterium-containing drug candidate for interstitial lung disease and other inflammatory and fibrotic diseases
Chen, M. C., Korth, C. C., Harnett, M. D., Elenko, E., & Lickliter, J. D. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1040 · Cited by 18
RNA Sequencing of Epithelial Cell/Fibroblastic Foci Sandwich in Idiopathic Pulmonary Fibrosis: New Insights on the Signaling Pathway
Calabrese, F., Lunardi, F., Tauro, V., Pezzuto, F., Fortarezza, F., Vedovelli, L., Faccioli, E., Balestro, E., Schiavon, M., Esposito, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063323 · Cited by 18
Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis
Kaul, B., Lee, J. S., Petersen, L. A., McCulloch, C. E., Rosas, I. O., Bandi, V., Zhang, N., DeDent, A. M., Collard, H. R., & Whooley, M. A. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.02.027 · Cited by 18
Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis
Zhao, J. L., Fares, J., George, G., Maheu, A. R., Loizidis, G., Roman, J., Kramer, D., Li, M., & Summer, R. S. (2023) · Respirology · doi:10.1111/resp.14563 · Cited by 18
Spatially resolved metabolomics visualizes heterogeneous distribution of metabolites in lung tissue and the anti-pulmonary fibrosis effect of Prismatomeris connate extract
Jiang, H., Zheng, B., Hu, G., Kuang, L., Zhou, T., Li, S., Chen, X., Li, C., Zhang, D., Zhang, J., et al. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.100971 · Cited by 15
Health disparities and associated social determinants of health in interstitial lung disease: a narrative review
Tikellis, G., & Holland, A. E. (2025) · European Respiratory Review · doi:10.1183/16000617.0176-2024 · Cited by 14
Citrus pectin-coated inhalable PLGA nanoparticles for treatment of pulmonary fibrosis
Perera, K. D. C., Ghumman, M., Sorkhdini, P., Norbrun, C., Negash, S., Zhou, Y., & Menon, J. U. (2025) · Journal of Materials Chemistry B · doi:10.1039/d4tb01682c · Cited by 14
Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population
Chérrez-Ojeda, I., Cortés-Telles, A., Gochicoa‐Rangel, L., Camacho-Leon, G., Mautong, H., Robles‐Velasco, K., & Faytong‐Haro, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091393 · Cited by 15
The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry
Lee, C. T., Hao, W., Burg, C., Best, J. H., Kolenic, G. E., & Strek, M. E. (2024) · Respiratory Research · doi:10.1186/s12931-024-02883-2 · Cited by 13
Interstitial Lung Disease and Sarcoidosis
Sharp, M., Mustafa, A., Farah, N., & Bonham, C. A. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2023.06.003 · Cited by 12
Pirfenidone: A Promising Drug in Ocular Therapeutics
Bisen, A. C., Agrawal, S., Rayiti, R., Sanap, S. N., Biswas, A., Mishra, A., Gupta, N. M., & Bhatta, R. S. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202301389 · Cited by 11
Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review
Han, M., Liu, Q., Ji, Z., Jin, L., Jin, W., & Gao, Z. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1411279 · Cited by 11
Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
Nathan, S. D., Smith, P., Deng, C., King, C. S., Salvo, M. D., Weigt, S. S., Pandya, S., Bandyopadhyay, D., Lasky, J. A., Krishna, R., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2501488 · Cited by 10
Focal adhesion kinase inhibitors in fibrotic diseases therapy: Development and therapeutic potential
Gan, C., Wei, W., Xue, T., Xie, Y., Yue, L., Su, X., Yan, Y., Liu, Z., & Ye, T. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117882 · Cited by 12
Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia
Assayag, D., Adegunsoye, A., Sheehy, R. D., Morisset, J., Khalil, N., Johannson, K. A., Marcoux, V. S., Kolb, M. R. J., Fisher, J. H., Manganas, H., et al. (2023) · CHEST Journal · doi:10.1016/j.chest.2022.12.039 · Cited by 10
Safety of Nintedanib in a Patient with Chronic Pulmonary Fibrosis and Kidney Disease
Maggisano, M., Mondini, L., Chernovsky, M., Confalonieri, P., Salton, F., Reccardini, N., Kodric, M., Geri, P., Confalonieri, M., Hughes, M., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17091147 · Cited by 9
Innovative phytoceutical-based drug delivery in the management of pulmonary fibrosis: A roadmap towards inhaled therapeutics
Wong, S. L., Gan, J. S., Rubis, G. D., Paudel, K. R., Yeung, S., Chellappan, D. K., Keng, P. S., & Dua, K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105942 · Cited by 8
Effect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis
Xu, H., Hui, S. L., Lee, J. S., Zhang, Z., & Boente, R. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202312-1054oc · Cited by 8
The Therapeutic Mechanism of Schisandrol A and Its Metabolites on Pulmonary Fibrosis Based on Plasma Metabonomics and Network Analysis
Qiaolongbatu, X., Zhao, W., Huang, X., Qian, F., Yang, X., Wu, J., Ma, C., Qu, H., Wang, L., Fan, G., et al. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s391503 · Cited by 8
Uptake of Antifibrotics for Patients with Idiopathic Pulmonary Fibrosis: 2016–2022
Shankar, D. A., Hawkins, F. J., Alysandratos, K., Wilson, K. C., Walkey, A. J., Bosch, N. A., & Law, A. C. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202308-697rl · Cited by 8
Trends of mortality from chronic respiratory diseases by sex and ethnicity in the USA: a secular analysis from 1979 to 2021 using data from death certificates
Meng, Y., Han, X., Ji, Q., Zhang, A., Zhan, Y., & Chen, X. (2024) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002296 · Cited by 7
National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care
Salonen, J., Purokivi, M., Hodgson, U., & Kaarteenaho, R. L. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001363 · Cited by 9
Inhibition of TGF-β1/Smad3 signaling by compound 5aa: A potential treatment for idiopathic pulmonary fibrosis
An, B., Fang, Y., Wang, L., Nie, W., Wang, M., Nie, H., Wu, C., & Wang, R. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107374 · Cited by 6
Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United States
Qiu, Y., Zhu, J., Chopra, P., Elpers, B., Dieyi, C., Byrne, C., Tang, J., Ye, W., Govindaraj, K., & Fischer, A. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241280704 · Cited by 6
Racial, Ethnic, Sex, and Gender Equity for Inclusive Interstitial Lung Disease Research: An Official American Thoracic Society Research Statement
Assayag, D., Adegunsoye, A., Khor, Y. H., Bonella, F., Borie, R., Buendía-Roldán, I., Chaudhuri, N., Gibson, K. F., Johannson, K. A., Kaminski, N., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202509-2336st · Cited by 7
The Impact of Nintedanib Dosing on Clinical Outcomes
LIMPER, A. H., Thao, V., Helfinstine, D. A., Sangaralingham, L. R., & Dempsey, T. M. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.09.030 · Cited by 6
Self-citation
Broad Adoption of Antifibrotics in Idiopathic Pulmonary Fibrosis: Still a Long Way to Go
Assayag, D. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202102-123ed · Cited by 6
Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
Khor, Y. H. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.07.033 · Cited by 7
The Impact of Chronic Comorbidities on Outcomes in Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Baig, S. H., & Yoo, E. J. (2024) · Life · doi:10.3390/life14010156 · Cited by 7
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial
Maher, T. M., Hamblin, M. J., Choi, W.-I., Case, A. H., Tomos, I. P., Tzouvelekis, A. E., Shore, J. E., Bergna, M. A., Golod, D., Elenko, E., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag155 · Cited by 4
Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland
Majewski, S., Górska, K., Lewandowska, K. B., Martusewicz-Boros, M. M., Sobiecka, M., & Piotrowski, W. J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1586197 · Cited by 4
Construction and Bioinformatics Analysis of ceRNA Regulatory Networks in Idiopathic Pulmonary Fibrosis
Zhang, M., Wu, X., Zhu, H., Fu, C., Yang, W., Jing, X. B., Liu, W., & Cheng, Y. (2024) · Biochemical Genetics · doi:10.1007/s10528-024-10853-y · Cited by 4
Inhibition of Transglutaminase 2 by a Selective Small Molecule Inhibitor Reduces Fibrosis and Improves Pulmonary Function in a Bleomycin Mouse Model
Wang, Z., Sriram, S., Ugwoke, C., Gale, Z., Tabrizi, M. E. A., & Griffin, M. (2025) · Cells · doi:10.3390/cells14070497 · Cited by 4
Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study
Graham, C. S., Bisson, B., Shore, J. E., Pardy, E., Salisbury, F., LANCASTER, L. H., & Kulkarni, T. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03689-8 · Cited by 4
Editorial: Epidemiology and risk factors for interstitial lung diseases
Jeganathan, N., Corte, T. J., & Spagnolo, P. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1384825 · Cited by 4
Transcription factor MEOX1 accelerates pulmonary fibrosis by regulating mitophagy and senescence
Fang, L., Lyu, L., Zhong, H., Lin, J., Ren, P., Wang, Y., Yin, Y., Zhang, M., & Qu, Y.-Q. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178043 · Cited by 3
P38 MAPK is involved in epigenetic regulation of fibrotic genes in replication induced senescence in lung fibroblasts
Zhu, S., Zhou, J. Q., Wang, K., Guo, M., & Sanders, Y. Y. (2026) · Aging · doi:10.18632/aging.206357 · Cited by 4
Targeted Drug Delivery System for Pulmonary Fibrosis: Design and Development of Biomaterials
Liu, J., Pan, Z., Khan, A., & Li, H. (2025) · BIO Integration · doi:10.15212/bioi-2025-0016 · Cited by 5
Polypharmacy and potentially inappropriate medication (PIM) use among older veterans with idiopathic pulmonary fibrosis (IPF) – a retrospective cohort study
Guidot, D. M., Pepin, M. J., Hastings, S. N., Tighe, R. M., & Schmader, K. E. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03611-2 · Cited by 3
Respiratory Diseases in Women
Han, M. K., Shteinberg, M., Assayag, D., Schleich, F., Pengo, M. F., Scicluna, V. M., Lombardi, C., Barrecheguren, M., & Jara‐Palomares, L. (2024) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2024.10.009 · Cited by 3
Comparing the Utilization of Antifibrotic Medications Based on Income Level
Dempsey, T. M., Thao, V., Helfinstine, D. A., Sangaralingham, L. R., & LIMPER, A. H. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.07.4215 · Cited by 2
Self-citation
Caring for Rural Patients With Interstitial Lung Disease
DeDent, A. M., Shore, J. E., Bascom, R., Reichuber, J., Scholand, M. B., Boente, R., Nambiar, A. M., Danoff, S. K., Rahaghi, F., Kulkarni, T., et al. (2025) · CHEST Pulmonary · doi:10.1016/j.chpulm.2025.100136 · Cited by 2
Use of Nintedanib for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States
Luo, Y., Assassi, S., Mayes, M. D., Frech, T., Steen, V. D., Richardson, C., Chung, L. S., Sandorfi, N., VanBuren, J. M., Harding, M. L., et al. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202410-1045rl · Cited by 2
Mefunidone treats pulmonary fibrosis by targeting SDH to regulate fibro-promoting macrophages
Zhang, X., He, Y., Long, L., Jiang, G., Yao, T., Cheng, X., Peng, Z., Hu, G., Tao, L., & Meng, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114971 · Cited by 2
Aiming to Improve Equity in Lung Health: Sex and Gender
Wojcik, R. M., & Morris, A. M. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2023.03.014 · Cited by 2
Predictive factors of mortality in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a novel prognostic scoring system.
Polat, G., Özdemir, Ö., Ermin, S., Unat, D. S., & Üçsular, F. D. (2024) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v41i2.13779 · Cited by 2
Rational design and synthesis of 6-(piperazin-1-yl)imidazo[1,2-b]pyridazine derivatives as dual FXR/PPARδ agonists for treatment of pulmonary fibrosis
Yue, L., Jiang, N., Fan, X., Xu, S., Yi, R., Lei, H., & Zhai, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118013 · Cited by 2
Looking Ahead
Johannson, K. A., Collard, H. R., & Richeldi, L. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.014 · Cited by 2
Research advances in self-assembled peptide delivery systems for fibrosis treatment
Zhang, Y., Su, D., & Wang, Y. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100043 · Cited by 1
Safety and Pharmacokinetic Data for Inhaled Administration of Nintedanib Dry Powder Inhalation for Treatment of Pulmonary Fibrotic Diseases
Fares, W. H., & Castagna, M. (2026) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1177/19412711251414386 · Cited by 1
Development and validation of a generalisable machine learning algorithm for identifying interstitial lung disease cohorts: a retrospective cohort study
Farrand, E. D., Chung, A., Joshua, J., Dong, H., Mills, H., Lee, A., Ieong, M. M., Radhakrishnan, L., Gologorskaya, O., & Butte, A. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103790 · Cited by 1
Geriatric nutritional risk index in antifibrotic therapy can predict tolerability and mortality risk
Masuda, T., Mochizuka, Y., Suzuki, Y., Kono, M., Matsushima, S., Kato, S., Suzuki, K., Tanaka, K., Koda, K., Masuda, T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-45792-8 · Cited by 1
Management of interstitial lung disease in systemic autoimmune rheumatic diseases: a survey of rheumatologists and pulmonologists
Braverman, G., Aronson, K. I., Thomas, C., & Spiera, R. (2026) · Rheumatology Advances in Practice · doi:10.1093/rap/rkag050 · Cited by 1
Systems pharmacology of traditional Chinese medicine in fibrosis: From multi-target mechanisms to translational validation
Foudah, A. I., & Alam, A. (2026) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2026.05.008 · Cited by 1
Health-related quality of life assessment using KBILD in fibrotic interstitial lung diseases receiving antifibrotic therapy: a prospective longitudinal study
Suzuki, Y., Kono, M., Matsushima, S., Kato, S., Suzuki, K., Tanaka, K., Koda, K., Masuda, T., Kanai, M., Ikeda, M., et al. (2026) · ERJ Open Research · doi:10.1183/23120541.00402-2026 · Cited by 1
A new perspective on idiopathic pulmonary fibrosis research: From multi-dimensional mechanistic exploration to advances in precision therapy
Zhang, S.-M., Huang, M.-Z., Wang, Y.-W., Wang, X.-F., Ding, Y., Li, J. Q., Zou, X.-M., & Ma, C. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108946 · Cited by 1
Prevalence of anxiety and depression in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
Xu, L., 臧丹阳, Yan, R., Liang, Z., Yang, S., Yu, N., & Yu, X. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04400-1 · Cited by 1
Interstitial Lung Disease in Veterans: Leveraging Big Data to Bridge Evidence and Practice Gaps
Kaul, B., Petersen, L. A., Rosas, I. O., Lee, J. S., Martínez, F. J., Bandi, V., Helmer, D. A., Wolters, P. J., Collard, H. R., & Whooley, M. A. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202211-942ps · Cited by 1
Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study
Lee, H. Y., Jung, S. Y., Jang, J. H., Ko, J., Kim, D.-W., Her, M., & Lee, J. H. (2023) · Life · doi:10.3390/life13112118 · Cited by 1
Inequity and the Interstitium: Pushing Back on Disparities in Fibrosing Lung Disease in the United States and Canada
Gaffney, A. W., & Podolanczuk, A. J. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202111-2652ed · Cited by 1
Insights from the INSIGHTS-ILD Registry: real-world heterogeneity in treatment patterns for patients with fibrotic interstitial lung disease
Ma, A., & Montesi, S. B. (2025) · ERJ Open Research · doi:10.1183/23120541.01395-2024 · Cited by 1
Adoption of Antifibrotic Medications: A Closer Look at the Data
White, E. S., Nili, M., Shetty, S. S., & Leonard, T. B. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202103-359le
Reply: Adoption of Antifibrotic Medications: A Closer Look at the Data
Dempsey, T. M., Payne, S. R., Sangaralingham, L. R., & LIMPER, A. H. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202104-516le
Self-citation
Einsatz antifibrotischer Medikamente bei interstitiellen Lungenerkrankungen
Kreutz, C.-P., Gesierich, W., Behr, J., & Kneidinger, N. (2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1825-4967
Clin‐STAR corner: Recent practice‐changing studies at the interface of pulmonary and critical care medicine and geriatrics
Jain, S., Witt, L. J., & Ferrante, L. E. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18196
Uncomfortable Truths About Data, Justice, and Idiopathic Pulmonary Fibrosis in the Veterans Health Administration
Locke, B. W., & Callahan, S. J. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.03.037
Geschlechtsspezifische Aspekte bei interstitiellen Lungenerkrankungen
Buschulte, K., & Polke, M. (2024) · Zeitschrift für Pneumologie · doi:10.1007/s10405-024-00551-2
Traditional Chinese Medicine in the Treatment of Post-Viral Interstitial Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
李, 亚. (2024) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2024.33091
The Impact of Obstructive Sleep Apnea on Idiopathic Pulmonary Fibrosis Clinical Outcomes
Hamza, A., Helfinstine, D. A., Herberts, M. B., Olson, E. J., Dempsey, T. M., & Limper, A. H. (2025) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-026-00054-2
Self-citation
Big Data: Pearls and Pitfalls for Precision Medicine in Interstitial Lung Disease
Kaul, B., Collard, H. R., & Petersen, L. A. (2025) · Respiratory medicine · doi:10.1007/978-3-031-87183-2_10
A phase 1 pharmacokinetics study of deupirfenidone (LYT-100) in healthy older adults
Maher, T. M., Chen, M. J., Korth, C. C., Elenko, E., Harnett, M. D., Garg, V., & Graham, C. S. (2025) · ERJ Open Research · doi:10.1183/23120541.00469-2025
Trends in Medicare Part D Spending on Antifibrotic Therapies for Pulmonary Fibrosis: 2019–2023Preprint
RIZLY, S., VAITHISWARAN, D., Lorenzana, A. M., & Saleh, A. G. (2025) · medRxiv · doi:10.1101/2025.08.01.25332591
Additional file 1 of Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment
Herberts, M. B., Teague, T., Thao, V., Sangaralingham, L. R., Henk, H. J., Hovde, K. T., Dempsey, T. M., & LIMPER, A. H. (2023) · Figshare · doi:10.6084/m9.figshare.23826911
Self-citation
Additional file 1 of The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry
Lee, C. T., Hao, W., Burg, C., Best, J. H., Kolenic, G. E., & Strek, M. E. (2024) · Figshare · doi:10.6084/m9.figshare.26737635
Economic Burden of Idiopathic Pulmonary Fibrosis: Updated Evidence on Costs and Resource Use
Diamantopoulos, A., Pople, O., Godman, A., & Papastergios, E. (2026) · PharmacoEconomics · doi:10.1007/s40273-026-01600-9
Current clinical practice including treatment patterns and pathways in idiopathic pulmonary fibrosis patients in China: A real-world analysis
Bao, H., Jian, Y., Penaloza-Ramos, C. M., Kanakapura, M., Deng, Z., Xuan, J., & Zhao, H. (2026) · Pharmacoeconomics and Policy · doi:10.1016/j.pharp.2026.03.005
Trends in annual prevalence and incidence of pharmacologically treated idiopathic pulmonary fibrosis in Greece (2019–2023): A nationwide e-prescription study
Kourlaba, G., Stefanou, G., Ravanidis, S., Mathioudakis, K., Tsolakidis, A., & Zografopoulos, D. (2026) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2026.101269
Impact of Antifibrotic Adherence and Dosing on Risk of Mortality and Hospitalization in Idiopathic Pulmonary Fibrosis
Xu, H., Meier, E., Chhabria, M., DeDent, A. M., Hui, S. L., Zhang, Z., & Boente, R. (2026) · CHEST Journal · doi:10.1016/j.chest.2026.03.040
Real-World Health Care Resource Utilization and Economic Burden Among Patients with Idiopathic Pulmonary Fibrosis in Commercially Insured and Medicare Advantage Populations in the United States
Yang, J., Fee, R. M., Steffens, A., Le, L., Bui, B. H., & Borah, B. J. (2026) · Journal of health economics and outcomes research · doi:10.36469/jheor.2026.161503
Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry
Chee, M., Khor, Y. H., Jackson, D., Cooper, W., D’Costa, J., de Boer, S., Edwards, A., Ellis, S. J., Gabbay, E., Gallagher, H., et al. (2026) · Internal Medicine Journal · doi:10.1111/imj.70490
Senescent fibroblasts in aging and pulmonary fibrosis
Palega, S., Borengasser, A. Y., & Sanders, Y. Y. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1816071
Evaluating prognostic value of the prognostic nutritional index, CRP-to-albumin ratio and lymphocyte-to-CRP ratio in patients with idiopathic pulmonary fibrosis
Zhang, Q., Ouyang, X., Tan, Y., Qian, Y., Song, M., & Peng, H. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2689565
Theranostic innovation in infectious lung diseases: integrating biotechnology and nanotechnology for precision medicine
Jafari, A., Manzari‐Tavakoli, A., Tavakoli, M. M., Hashemian, S. M., Jamaati, H., Akhtari, M., Tabarsi, P., & Omrani, M. (2026) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2026.2714060
The anti-fibrotic effects of irisolidone via peroxisome proliferator-activated receptor gamma
Pan, Z.-A., Tong, L.-T., & Wang, Z.-M. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103916
Efficacy and Safety of Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
Bajpai, J., Pradhan, A. K., Manek, G., Maurya, S., Kant, S., & Perrone, M. A. (2026) · Advances in respiratory medicine · doi:10.3390/arm94050073

Authors: Dempsey, T. M., Payne, S., Sangaralingham, L., Yao, X., Shah, N. D., & Limper, A. H.
Affiliations: Department of Pulmonary and Critical Care Medicine
Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
Mayo Clinic (US)
Corresponding author: Dempsey, Timothy M.
ORCID: Dempsey, Timothy M.
Payne, Stephanie
Sangaralingham, Lindsey
Yao, Xiaoxi
Shah, Nilay D.
Limper, Andrew H.
Venue: Annals of the American Thoracic Society
Publisher: Oxford University Press (OUP)
Published: 2021-07-01
Volume: 18
Issue: 7
Pages: 1121-1128
ISSN: 2325-6621 (ISSN-L)
2329-6933
DOI: 10.1513/annalsats.202007-901oc
OpenAlex: W3122584685
Cited by: 101
References: 33
Citations by year: 2026: 24 · 2025: 21 · 2024: 22 · 2023: 14 · 2022: 11 · 2021: 9
FWCI: 9.09
Type: journal article
Language: en
Open access: closed
Licence: academic.oup.com/pages/standard-publication-reuse-rights (vor)
Locations: Annals of the American Thoracic Society (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords: idiopathic pulmonary fibrosis, pirfenidone, nintedanib, antifibrotic agents, treatment persistence, out-of-pocket costs, prescription drug costs, Medicare Advantage beneficiaries, real-world applications, drug approval
MeSH terms: Aged, Pharmaceutical Preparations, Female, Medicare, Humans, Indoles, Male, Pyridones, Retrospective Studies, United States, Treatment Outcome, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks